GENTICEL 
Genticel is a clinical stage biopharmaceutical company that develops multivalent vaccines for patients infected with Human Papillomavirus (HPV). Till date, the company has raised EUR 27 Mio in funding.
Current investors include Edmond de Rothschild Venture Partners, Innobio Fund, IDInvest (Allianz) and Amundi.
Our lead investigational vaccine, ProCervix, has successfully finished a very positive data-rich Phase Ib trial on 47 HPV16 and/or 18 infected women. ProCervix is the first therapeutic vaccine offering a solution to the more than 93 million women worldwide already infected with HPV 16 and/or 18 before the appearance of high grade neoplasia. This very large population, exposed at high risk to develop cervical cancer, is only now becoming accessible thanks to new screening guidelines prescribing first line HPV-based testing.
A large survey of prescribers and a Market Access Study predict overwhelming acceptability and a very large market potential.
Genticel wants to take ProCervix into Clinical Phase II and further develop our second product, a heptavalent therapeutic HPV vaccine, up to clinical stage.
To do this, we intend to raise additional capital from our current and selected international investors.
